Floatz logo

Palmitic Monoethanolamide

Migraine Disorder

RDC Clinical Pty LtdSmall moleculePhase 3Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
73/ 100

Competitive context

100 Active assets in the Migraine Disorder cohort.

Asset / SponsorPhaseRating
Atogepant
Stanford University
Phase 4A
Rizatriptan
Antonios Likourezos
Phase 4A
Zolmitriptan
Zosano Pharma Corporation
Phase 4A
Naproxen
IRCCS San Raffaele Roma
Phase 4A
Eptinezumab
Stanford University
Phase 4BBB

View all 50 →

Same molecule, other indications

Palmitic Monoethanolamide is also rated in:

chronic prostatitisActive
BB
Indicative · Phase 4
69 / 100
View asset →
chronic pain syndromeActive
BB
Indicative · Phase 4
66 / 100
View asset →
bipolar depressionActive
B
Indicative · Phase 2
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →